Short answer
Zimmer Biomet (ZBH) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Operating-segment recast reflects changed CODM reporting responsibilities beginning Q1 2026.
Zimmer Biomet 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Operating-segment recast reflects changed CODM reporting responsibilities beginning Q1 2026
- Europe, Middle East and Africa plus Asia Pacific Foot and Ankle results moved into Americas
- Centralized R&D and global marketing expenses now allocated to Americas
- 2025 MD&A and financial statements recast for comparability, without changing reported company-wide results
- Investors should use Exhibit 99.1 for revised segment analysis and avoid relying on prior segment comparisons
Item EX-99.1 · Exhibit EX-99.1
- Exhibit recasts 2025 Form 10-K segment information only; no underlying financial restatement or broader update
- Foot and Ankle EMEA and Asia Pacific results shifted into the Americas operating segment
- Centralized R&D and global marketing expenses now allocated to Americas, reducing comparability with prior segment reporting
- Investors should use the recast MD&A and segment disclosures when assessing 2025 segment performance and 2026 trends
- 2025 net sales $8,231.5 million, up 7.2%; operating profit margin 13.3% versus 16.7% in 2024
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Zimmer Biomet 8-K filings
Get the next ZBH 8-K as it lands
Follow ZBH for push alerts, or ask the research agent what this filing means.